A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the agency's website, as the Trump administration halts DEI initiatives.
The U.S. Food and Drug Administration has officially banned red dye — called Red 3, or Erythrosine — from foods, dietary supplements and ingested medicines, as reported on Wednesday.
Merck & Co (NYSE:MRK) said on Monday that the U.S. Food and Drug Administration (FDA) has granted priority review to its application for expanded use of the oral cancer drug Welireg.
The Food and Drug Administration (FDA) announced Wednesday it will ban Red No. 3, a common artificial food dye linked
Northwell Health partnered with Stacker to explore how a new Pap smear alternative may help prevent deaths from cervical cancer.
The artificial food dye can be found in candy, beverages, chips and other packaged foods — often consumed by children.
Over 35 years after the first study linking the artificial food dye Red 3 to thyroid cancer in rats was published, the U.S. is beginning to phase it out of foods and drugs.
The FDA has banned red dye No. 3 in food and ingested drugs, the agency announced. But what exactly is red dye No. 3, and why is it being banned? Here's what you need to know.
29,885 people played the daily Crossword recently. Can you solve it faster than others?29,885 people played the daily Crossword recently. Can you solve it faster than others? A woman regained ...
The U.S. Food and Drug Administration wants to put nutrition information front and center on food products to give consumers an easier way to identify nutrients linked to chronic diseases. The FDA announced its plans to push for a rule that would require food manufacturers to include a front-of-package nutrition label on most packaged food products.
Already banned in cosmetics and topical medicines since 1990, the Food and Drug Administration announced on Wednesday that Red 3 will now be banned in food, drink, and ingestible medications.
The regulatory agency will review MSD’s new drug application (NDA) for Welireg under a Priority Review, with a Prescription Drug User Fee Act (PDUFA) target action date of 26 May 2025. The new label is intended to cover adult and paediatric patients aged 12 years and older with advanced, unresectable, or metastatic PPGL.